TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12574224
Drug: Hyperthyroid patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthyroid patients during treatment
Study: 12574224
Drug: Hyperthyroid patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthyroid patients after treatment
Study: 8867434
Drug: iomeprol 350
Normalized name: Iomeprol 350 MG/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: iomeprol 350 mg/ml
Study: 8867434
Drug: iopentol 350
Normalized name: iopentol 350 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopentol 350 mg/ml
Study: 1653674
Drug: Insulin (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (0.15 units/kg)
Study: 3880557
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg daily, morning dosage at 9 am for 5 days)
Study: 3880557
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg daily, evening dosage at 9 pm for 5 days)
Study: 3880557
Drug: Omeprazole (morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (morning dosage)
Study: 3880557
Drug: Omeprazole (evening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (evening dosage)
Study: 17913970
Drug: Ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 750 mg alone
Study: 17913970
Drug: Ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 750 mg plus lanthanum carbonate 1 g three times daily with meals
Study: 11389423
Drug: Chronic venous
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic venous ulcer wound fluid (CVUWF, 300 microg protein/mL)
Study: 11445756
Drug: Creatine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (0.3 g.kg(‐1) Cr monohydrate for 7 days)
Study: 29458447
Drug: Self-monitoring urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-monitoring urinary salt excretion using a self-measuring device for 4 weeks
Study: 29458447
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (urine salt excretion measured but results not disclosed)
Study: 15938536
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lisinopril with indapamid
Study: 15938536
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of egilok+hypothiaside
Study: 15938536
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diroton+indap
Study: 15938536
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cordipin-retard+hypothiaside
Study: 15938536
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of renitek-hypothiaside
Study: 12117883
Drug: L-NMMA 4
Normalized name: 4-hydroxy-L-phenylalanine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-NMMA 4 mg/kg/h
Study: 12117883
Drug: L-NMMA 8
Normalized name: 8-L-lysinevasopressin
DrugBank: Lypressin (DB14642)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-NMMA 8 mg/kg/h
Study: 2349371
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg naloxone intravenous injection
Study: 26755382
Drug: Tocilizumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (40 mg) + 1-2 mL of 0.5% bupivacaine
Study: 20110402
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment at a dose of 2 mg/m(2) per day until the onset of puberty for at least 2 years.
Study: 16392436
Drug: Pumpan® (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pumpan® (3 × 10 drops daily for 6 weeks)
Study: 30888835
Drug: HCL AP
Normalized name: AP-101
DrugBank: AP-101 (DB17947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCL AP therapy with the Control-IQ system
Study: 30888835
Drug: SAP therapy
Normalized name: Bambusa vulgaris sap extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAP therapy with remote monitoring
Study: 22864520
Drug: Adrenalized infraclavicular
Normalized name: adrenal cortex extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenalized infraclavicular lidocaine 2% 10 ml + ropivacaine 0.75% 20 ml ('long acting', n=90)
Study: 22864520
Drug: Adrenalized infraclavicular
Normalized name: adrenal cortex extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenalized infraclavicular lidocaine 1.5% 30 ml + long-acting distal median, radial, and ulnar nerve blocks ('short acting', n=87)
Study: 20143047
Drug: Combined drug
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined drug and behavioral therapy
Study: 17650661
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) treatment (5‐10 mA, 80‐100 Hz, 30 min stimulation, once daily for 10 days)
Study: 17650661
Drug: Cetirizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (10 mg/times, t.i.d, peros)
Study: 12234851
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied one time per week
Study: 12234851
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied two times per week
Study: 12234851
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied three times per week
Study: 12234851
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream (all dosing regimens)
Study: 9612628
Drug: Various antibiotics
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various antibiotics
Study: 7817332
Drug: Benzodiazepine (lormetazepam,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine (lormetazepam, 2 mg)
Study: 16245354
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) for 5 years (20 mg/day)
Study: 16245354
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) for 2 years (20 mg/day)
Study: 11886196
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (SC and CC)
Study: 7660449
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg DEC once daily for 12 days
Study: 7660449
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg DEC given 3 times daily for 12 days
Study: 7660449
Drug: All 3
Normalized name: Small 33G Lancet
Approvals — FDA: no, EMA: no, PMDA: no
Description: All 3 treatment regimens (6 mg/kg once daily, 2 mg/kg three times daily, and unspecified third regimen)
Study: 2913493
Drug: Outpatient detoxification
Normalized name: ARTEMISIA VULGARIS ROOT 4.5 mg in 30 mg / CINNAMON 3 mg in 30 mg / CALENDULA OFFICINALIS FLOWER 4.5 mg in 30 mg / MENTHA PIPERITA LEAF 9 mg in 30 mg TOPICAL LIQUID [HOUKEA Lymphatic Detoxification Anti-Inflammatory Slimming Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient detoxification with decreasing doses of oxazepam
Study: 2913493
Drug: Inpatient detoxification
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient detoxification with oxazepam and rehabilitation treatment
Study: 972787
Drug: Oral riboflavin
Normalized name: riboflavin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral riboflavin with blue light energy of 6-7 muW/cm2
Study: 7303703
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg beta‐methyldigoxin (Lanitop) daily, orally
Study: 7303703
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg beta‐acetyldigoxin (Novodigal) daily, orally
Study: 15078004
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg b.i.d. x 7 days)
Study: 15078004
Drug: Amoxicillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (1 g t.i.d. x 7 days)
Study: 9919896
Drug: Itraconazole 400
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole 400 mg daily for 1 week
Study: 8186139
Drug: Itraconazole 100
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 100 mg daily for 4 weeks
Study: 8311214
Drug: Intra-articular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular morphine (1 mg)
Study: 3138057
Drug: Vamin 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vamin 14 infusion
Study: 28314613
Drug: Ultra-low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low dose (ULD) protocols (I: 100kVp/50 mAs, II: 100kVp/75 mAs, III: 100kVp/100 mAs, IV: 120kVp/100 mAs)
Study: 28314613
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (LD) protocols (I: 100kVp/75 mAs, II: 100kVp/100 mAs, III: 100kVp/150 mAs, IV: 120kVp/150 mAs)
Study: 16731321
Drug: Cisatracurium plus
Normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisatracurium plus 3 mg/kg lidocaine
Study: 16731321
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (3 mg/kg lidocaine diluted with saline)
Study: 15256690
Drug: Acute Rhodiola
Normalized name: RHODIOLA ROSEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute Rhodiola rosea intake (200 mg extract containing 3% rosavin + 1% salidroside)
Study: 15256690
Drug: Acute Rhodiola
Normalized name: RHODIOLA ROSEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute Rhodiola rosea intake (200 mg extract)
Study: 8858190
Drug: Dopamine agonists
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonists (pergolide, bromocriptine, cabergoline)
Study: 8858190
Drug: Catechol-O-methyltransferase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catechol-O-methyltransferase inhibitors (tolcapone, entacapone)
Study: 8858190
Drug: Selegiline therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline therapy
Study: 1862015
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg ibuprofen controlled-release tablet (CRT)
Study: 1862015
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg ibuprofen controlled-release tablet (CRT)
Study: 6869899
Drug: Cimetidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (300 mg orally the evening before and 300 mg intramuscularly between 1 and 3 h preoperatively)
Study: 6869899
Drug: Antacid (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid (30 ml of Mylanta-II orally on both occasions)
Study: 18838500
Drug: Dopamine agonist
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonist (pramipexole 0.5 mg)
Study: 18838500
Drug: Dopamine antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine antagonist (sulpiride 400 mg)
Study: 12904518
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy with micronized 17beta‐estradiol alone
Study: 12904518
Drug: 17beta‐estradiol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta‐estradiol plus sequentially administered medroxyprogesterone acetate
Study: 8889422
Drug: Priming dose
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming dose of 0.01 mg kg‐1 followed by 0.07 mg kg‐1 after 3-4 min
Study: 8889422
Drug: Priming dose
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming dose of 0.015 mg kg‐1 followed by 0.065 mg kg‐1 after 3-4 min
Study: 8889422
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus injection of 0.08 mg kg‐1
Study: 6308441
Drug: Ketoconazole 400
Normalized name: ketoconazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 400 mg daily p.o.
Study: 31192738
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml of honey with an ORS at every diarrhea episode
Study: 31192738
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of honey added to an ORS at every diarrhea episode
Study: 24578471
Drug: 1.4% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4% sodium bicarbonate hydration (250 mL) prior to CE-CT
Study: 24578471
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline hydration (1000 mL) prior to and after CE-CT
Study: 20579907
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Treatment Group
Study: 16117878
Drug: Prophylactic cranial
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic cranial irradiation (PCI) at a dose of 25.2 to 30.6 Gy in 1.8 to 2.0 Gy per fraction
Study: 1440822
Drug: Albendazole 400
Normalized name: albendazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 400 mg once daily for 21 days
Study: 3698061
Drug: Wax/polymer matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wax/polymer matrix tablet 60 mEq/day (20 mEq TID)
Study: 3698061
Drug: Powder-in-liquid formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder-in-liquid formulation 60 mEq/day (20 mEq TID)
Study: 29383408
Drug: 400 IU
Normalized name: Vitamin D 400 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU of nasal salmon calcitonin daily for three months
Study: 18425398
Drug: UFT (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (300 mg/day, three days after TACE)
Study: 12892766
Drug: Intracoronary radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary radiation therapy (IRT) with Sr-90
Study: 10848883
Drug: DHEA 50
Normalized name: Natrol Mood & Stress DHEA 50mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 50 mg and 200 mg
Study: 9665269
Drug: BPI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPI treatment
Study: 8172749
Drug: Iopentol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopentol (300 mg I/ml), 2 ml/kg b.w. with an upper limit of 100 ml
Study: 8172749
Drug: Iohexol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iohexol (300 mg I/ml), 2 ml/kg b.w. with an upper limit of 100 ml
Study: 23553534
Drug: Intravenous zanamivir
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zanamivir 1200 mg
Study: 23553534
Drug: Intravenous zanamivir
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zanamivir placebo
Study: 23553534
Drug: Oral moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral moxifloxacin placebo
Study: 20840754
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride 15 mg TID
Study: 20840754
Drug: Oxybutynin hydrochloride
Normalized name: Oxybutynin hydrochloride
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxybutynin hydrochloride 2.5 mg TID
Study: 18385265
Drug: Sugammadex 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 2.0 mg kg(‐1) for reversal of rocuronium 0.6 mg kg(‐1)
Study: 18385265
Drug: Neostigmine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 50 microg kg(‐1) for reversal of cisatracurium 0.15 mg kg(‐1)
Study: 12797397
Drug: Time-intensified FEC-G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-intensified FEC-G (500, 75, 500 every 14 days) with lenograstim (G-CSF 150 microg/m2/day s.c. for 10 days)
Study: 12797397
Drug: Standard-dose FEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose FEC (500, 75, 500 every 21 days) with lenograstim (G-CSF 150 microg/m2/day s.c. for 10 days)
Study: 12797397
Drug: Time-intensified MMM-G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-intensified MMM-G (mitoxantrone 10, methotrexate 35 every 14 days and mitomycin C 10 every 28 days) with lenograstim (G-CSF 150 microg/m2/day s.c. for 10 days)
Study: 12797397
Drug: Time-intensified FEC-G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-intensified FEC-G
Study: 12797397
Drug: Standard-dose FEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose FEC
Study: 12797397
Drug: Both intensified
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both intensified regimens (FEC-G and MMM-G)
Study: 12797397
Drug: Both anthracycline-containing
Normalized name: methacycline
DrugBank: Metacycline (DB00931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both anthracycline-containing regimens (FEC-G and standard FEC)
Study: 10895336
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine 0.1 mg/kg for intra- and postoperative analgesia
Study: 1577049
Drug: Intraarticular indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarticular indomethacin 10 mg
Study: 31379118
Drug: Magnesium isoglycyrrhizinate
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium isoglycyrrhizinate (MgIG) low dose (Group A)
Study: 31379118
Drug: Magnesium isoglycyrrhizinate
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium isoglycyrrhizinate (MgIG) high dose (Group B)
Study: 29171661
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal oxygen at a flow rate of 30-70 l.min-1 via nasal cannulae
Study: 29171661
Drug: Standard oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oxygen therapy at 10 l.min-1 via a bite block
Study: 27418275
Drug: mHealth device
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth device plus weekly motivational support
Study: 22196778
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (aspirin, thienopyridine, and vitamin K antagonist)
Study: 20691446
Drug: COX-1 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: COX-1 gene polymorphisms (‐842A>G and 50C>T)
Study: 12095064
Drug: Tretinoin 0.1%
Normalized name: TRETINOIN 0.1% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin 0.1% microsponge gel
Study: 10194968
Drug: Response preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Response preparation initiated with a precue (colored square)
Study: 10194968
Drug: Response preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Response preparation during memory scanning
Study: 10194968
Drug: Difficulty of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difficulty of concurrent memory search
Study: 7748046
Drug: Class I
Normalized name: HLA class I antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class I and III antiarrhythmic drugs
Study: 25588
Drug: Prolyl-leucyl-glycinamide (MIF-I)
Normalized name: L-valine, l-tyrosyl-l-leucyl-l-.alpha.-glutamyl-l-prolylglycyl-l-prolyl-l-valyl-l-threonyl-
DrugBank: Ovemotide (DB19156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolyl-leucyl-glycinamide (MIF-I) 75 mg/day
Study: 25588
Drug: Prolyl-leucyl-glycinamide (MIF-I)
Normalized name: L-valine, l-tyrosyl-l-leucyl-l-.alpha.-glutamyl-l-prolylglycyl-l-prolyl-l-valyl-l-threonyl-
DrugBank: Ovemotide (DB19156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolyl-leucyl-glycinamide (MIF-I) 750 mg/day
Study: 12610404
Drug: Anesthetic blocks
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthetic blocks of a compound of bupivacaine with adrenaline associated with clonidine at the frontal branch and sometimes the nasal branch levels of the ophthalmic nerve.
Study: 11120691
Drug: Cariporide 120
Normalized name: Cariporide
DrugBank: Cariporide (DB06468)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariporide 120 mg every 8 hours
Study: 11120691
Drug: Cariporide 20
Normalized name: Cariporide
DrugBank: Cariporide (DB06468)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariporide 20 mg every 8 hours
Study: 11120691
Drug: Cariporide 80
Normalized name: Cariporide
DrugBank: Cariporide (DB06468)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariporide 80 mg every 8 hours
Study: 8269445
Drug: 3-mg tablets
Normalized name: lusutrombopag 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-mg tablets of reformulated, micronized glyburide (Glynase PresTab tablets)
Study: 8269445
Drug: 5-mg tablets
Normalized name: dronabinol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg tablets of original glyburide (Micronase tablets)
Study: 3884218
Drug: Pseudoephedrine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine (4 mg/kg/day)
Study: 3884218
Drug: Chlorpheniramine (0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine (0.35 mg/kg/day)
Study: 29848328
Drug: Micro-fragmented adipose
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-fragmented adipose tissue injection
Study: 31694851
Drug: Intravenous sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sildenafil (loading dose of 0.4 mg/kg in 3 hours; followed by continuous infusion of 1.6 mg/kg/day)
Study: 31694851
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) (dosed at 20 ppm)
Study: 25158846
Drug: Standard moist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard moist wound therapy
Study: 17293706
Drug: Metformin (850-2550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850-2550 mg/day)
Study: 10411245
Drug: Sarns oxygenator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarns oxygenator with 0.0375 g of albumin/100 ml prime